395 related articles for article (PubMed ID: 25139423)
21. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration.
Palhan VB; Chen S; Peng GH; Tjernberg A; Gamper AM; Fan Y; Chait BT; La Spada AR; Roeder RG
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8472-7. PubMed ID: 15932940
[TBL] [Abstract][Full Text] [Related]
22. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
23. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
[TBL] [Abstract][Full Text] [Related]
24. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3.
Jeub M; Herbst M; Spauschus A; Fleischer H; Klockgether T; Wuellner U; Evert BO
Exp Neurol; 2006 Sep; 201(1):182-92. PubMed ID: 16765348
[TBL] [Abstract][Full Text] [Related]
25. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Cummings CJ; Orr HT; Zoghbi HY
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
[TBL] [Abstract][Full Text] [Related]
26. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid attenuates the suppression of acetyl histone H3 and CREB activity in an inducible cell model of Machado-Joseph disease.
Lin XP; Feng L; Xie CG; Chen DB; Pei Z; Liang XL; Xie QY; Li XH; Pan SY
Int J Dev Neurosci; 2014 Nov; 38():17-22. PubMed ID: 25068645
[TBL] [Abstract][Full Text] [Related]
28. A role for both wild-type and expanded ataxin-7 in transcriptional regulation.
Ström AL; Forsgren L; Holmberg M
Neurobiol Dis; 2005 Dec; 20(3):646-55. PubMed ID: 15936949
[TBL] [Abstract][Full Text] [Related]
29. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
30. Schwann cell involvement in the peripheral neuropathy of spinocerebellar ataxia type 3.
Suga N; Katsuno M; Koike H; Banno H; Suzuki K; Hashizume A; Mano T; Iijima M; Kawagashira Y; Hirayama M; Nakamura T; Watanabe H; Tanaka F; Sobue G
Neuropathol Appl Neurobiol; 2014 Aug; 40(5):628-39. PubMed ID: 23617879
[TBL] [Abstract][Full Text] [Related]
31. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
Griffin JL; Cemal CK; Pook MA
Physiol Genomics; 2004 Feb; 16(3):334-40. PubMed ID: 14679302
[TBL] [Abstract][Full Text] [Related]
32. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis.
Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK
PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985
[TBL] [Abstract][Full Text] [Related]
33. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.
Rüb U; de Vos RA; Brunt ER; Sebestény T; Schöls L; Auburger G; Bohl J; Ghebremedhin E; Gierga K; Seidel K; den Dunnen W; Heinsen H; Paulson H; Deller T
Brain Pathol; 2006 Jul; 16(3):218-27. PubMed ID: 16911479
[TBL] [Abstract][Full Text] [Related]
34. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.
Jung J; Xu K; Lessing D; Bonini NM
Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548
[TBL] [Abstract][Full Text] [Related]
35. Induction of cerebellar long-term depression requires activation of calcineurin in Purkinje cells.
Fujiwara A; Kakizawa S; Iino M
Neuropharmacology; 2007 Jun; 52(8):1663-70. PubMed ID: 17485101
[TBL] [Abstract][Full Text] [Related]
36. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3.
Evert BO; Vogt IR; Vieira-Saecker AM; Ozimek L; de Vos RA; Brunt ER; Klockgether T; Wüllner U
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1006-18. PubMed ID: 14575237
[TBL] [Abstract][Full Text] [Related]
38. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
Jia D; Jiang H; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
[TBL] [Abstract][Full Text] [Related]
39. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3.
Shakkottai VG; do Carmo Costa M; Dell'Orco JM; Sankaranarayanan A; Wulff H; Paulson HL
J Neurosci; 2011 Sep; 31(36):13002-14. PubMed ID: 21900579
[TBL] [Abstract][Full Text] [Related]
40. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.
Watchon M; Robinson KJ; Luu L; An Y; Yuan KC; Plenderleith SK; Cheng F; Don EK; Nicholson GA; Lee A; Laird AS
FASEB J; 2024 Jan; 38(2):e23429. PubMed ID: 38258931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]